Sandbox:Amd: Difference between revisions
Jump to navigation
Jump to search
Line 14: | Line 14: | ||
! colspan="2" rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Mechanism | ! colspan="2" rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Mechanism | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Etiology | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Etiology | ||
! colspan=" | ! colspan="6" style="background:#4479BA; color: #FFFFFF;" |Clinical manifestations | ||
! colspan="5" style="background:#4479BA; color: #FFFFFF;" |Paraclinical findings | ! colspan="5" style="background:#4479BA; color: #FFFFFF;" |Paraclinical findings | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Comments | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" |Comments | ||
|- | |- | ||
! colspan=" | ! colspan="6" style="background:#4479BA; color: #FFFFFF;" |Symptoms and signs | ||
! colspan="5" style="background:#4479BA; color: #FFFFFF;" |Lab findings/Urine exam | ! colspan="5" style="background:#4479BA; color: #FFFFFF;" |Lab findings/Urine exam | ||
|- | |- | ||
Line 27: | Line 27: | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |Hematuria | | align="center" style="background:#4479BA; color: #FFFFFF;" |Hematuria | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |Proteinuria | | align="center" style="background:#4479BA; color: #FFFFFF;" |Proteinuria | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |Serum osmolarity | | align="center" style="background:#4479BA; color: #FFFFFF;" |Serum osmolarity | ||
| align="center" style="background:#4479BA; color: #FFFFFF;" |S. ADH | | align="center" style="background:#4479BA; color: #FFFFFF;" |S. ADH | ||
Line 42: | Line 41: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
Line 48: | Line 46: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Improves urine osmolarity | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Improves urine osmolarity | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No improvement | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |No improvement | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Increased thirst | ||
|- | |- | ||
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Increased solute excretion | ! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Increased solute excretion | ||
Line 59: | Line 57: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Late stage | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Late stage | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |High in Type 2 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |High in Type 2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
Line 65: | Line 62: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |No effect | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hyperosmolar hyperglycemic state]] | ||
|- | |- | ||
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Salt loss | ! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Salt loss | ||
Line 74: | Line 71: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 84: | Line 80: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral salt-wasting syndrome]] | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cerebral salt-wasting syndrome]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 107: | Line 102: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |High | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |High | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Low | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Low | ||
Line 118: | Line 112: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |– | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |High | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |High | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal | ||
Line 132: | Line 125: | ||
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Renal disease | ! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Renal disease | ||
| style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Renal tubular acidosis]]<ref name="pmid19721811">{{cite journal| author=Pereira PC, Miranda DM, Oliveira EA, Silva AC| title=Molecular pathophysiology of renal tubular acidosis. | journal=Curr Genomics | year= 2009 | volume= 10 | issue= 1 | pages= 51-9 | pmid=19721811 | doi=10.2174/138920209787581262 | pmc=2699831 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19721811 }}</ref> | | style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Renal tubular acidosis]]<ref name="pmid19721811">{{cite journal| author=Pereira PC, Miranda DM, Oliveira EA, Silva AC| title=Molecular pathophysiology of renal tubular acidosis. | journal=Curr Genomics | year= 2009 | volume= 10 | issue= 1 | pages= 51-9 | pmid=19721811 | doi=10.2174/138920209787581262 | pmc=2699831 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19721811 }}</ref> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 159: | Line 151: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |- | ||
! colspan="2" |Miscellaneous | |||
|[[Benign Prostatic Hyperplasia (BPH)]]<ref name="pmid16379182">{{cite journal| author=Yoong HF, Sundaram MB, Aida Z| title=Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia. | journal=Med J Malaysia | year= 2005 | volume= 60 | issue= 3 | pages= 294-6 | pmid=16379182 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16379182 }}</ref> | |||
| + | |||
| + | |||
| + | |||
| + | |||
|± | |||
|– | |||
|Normal | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
|} | |} |
Revision as of 17:05, 11 May 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Differential diagnosis
Abbreviations: Na= Natrium/ Sodium, ADH= Antidiuretic hormone
POLYURIA
Mechanism | Etiology | Clinical manifestations | Paraclinical findings | Comments | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms and signs | Lab findings/Urine exam | |||||||||||||
Dysuria | Nocturia | Hesitancy | Dribbling | Hematuria | Proteinuria | Serum osmolarity | S. ADH | Urine osmolarity | Water deprivation test | ADH administration | ||||
Increased intake of fluid | Psychogenic polydipsia[1] | – | – | – | – | – | – | Normal | Normal | Low | Improves urine osmolarity | No improvement | Increased thirst | |
Increased solute excretion | Osmotic causes | Diabetes mellitus[2] | – | ± | – | – | – | Late stage | High in Type 2 | Normal | Normal | No effect | No effect | Hyperosmolar hyperglycemic state |
Salt loss | Diuretics | – | + | – | + | – | ||||||||
Cerebral salt-wasting syndrome | ||||||||||||||
Impaired urinary concentration | Low ADH | Central diabetes insipidus | – | + | – | – | ± | ± | High | Low | Low | No improvement | Urine osmolarity improves | |
Nephrogenic diabetes insipidus | – | + | – | ± | ± | High | Normal | Low | No improvement | No improvement | ||||
Renal disease | Renal tubular acidosis[3] | |||||||||||||
Bartter syndrome | ||||||||||||||
Miscellaneous | Benign Prostatic Hyperplasia (BPH)[4] | + | + | + | + | ± | – | Normal |
Differential diagnosis
Abbreviations: AP= Anteroposterior, CXR= Chest X-ray, CT= Computed tomography, ABG= Arterial blood gas, V/Q= Ventilation/perfusion scan , EKG= Electrocardiogram, COPD= Chronic obstructive pulmonary disease, BNP= Brain natriuretic peptide, DVT= Deep vein thrombosis, HRCT= High Resolution CT, IgE= Immunoglobulin E
|
References
- ↑ Mellinger RC, Zafar MS (1983). "Primary polydipsia. Syndrome of inappropriate thirst". Arch Intern Med. 143 (6): 1249–51. PMID 6860053.
- ↑ Ahloulay M, Schmitt F, Déchaux M, Bankir L (1999). "Vasopressin and urinary concentrating activity in diabetes mellitus". Diabetes Metab. 25 (3): 213–22. PMID 10499190.
- ↑ Pereira PC, Miranda DM, Oliveira EA, Silva AC (2009). "Molecular pathophysiology of renal tubular acidosis". Curr Genomics. 10 (1): 51–9. doi:10.2174/138920209787581262. PMC 2699831. PMID 19721811.
- ↑ Yoong HF, Sundaram MB, Aida Z (2005). "Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia". Med J Malaysia. 60 (3): 294–6. PMID 16379182.
- ↑ Cherry, James D. (2008). "Croup". New England Journal of Medicine. 358 (4): 384–391. doi:10.1056/NEJMcp072022. ISSN 0028-4793.
- ↑ Khurshid I, Downie GH (2002). "Pulmonary arteriovenous malformation". Postgrad Med J. 78 (918): 191–7. PMC 1742331. PMID 11930021.
- ↑ Doshi HM, Robinson S, Chalhoub T, Jack S, Denison A, Gibson G (2009). "Massive spontaneous hemothorax during the immediate postpartum period". Tex Heart Inst J. 36 (3): 247–9. PMC 2696501. PMID 19568398.
- ↑ Chanatry BJ (1992). "Acute hemothorax owing to pulmonary arteriovenous malformation in pregnancy". Anesth. Analg. 74 (4): 613–5. PMID 1554132.